GSK plc (LSE/NYSE: GSK) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to risvutatug rezetecan (also known as Ris-Rez), an investigational B7-H3-targeted antibody-drug conjugate (ADC), for the treatment of small-cell lung cancer (SCLC).
This milestone marks the sixth global regulatory designation for the asset, reinforcing its potential as a transformational therapy for aggressive solid tumors. The designation is supported by preliminary clinical data from the Phase I ARTEMIS-001 trial, which demonstrated durable responses in patients with extensive-stage small-cell lung cancer (ES-SCLC).
Clinical & Regulatory Milestone Summary
The following table outlines the current clinical status and the rapid regulatory momentum of risvutatug rezetecan:
| Feature | Details |
| Drug Name | Risvutatug rezetecan (Ris-Rez / GSK’227) |
| Mechanism of Action | B7-H3-targeted ADC with a topoisomerase inhibitor payload |
| Supporting Trial | Phase I ARTEMIS-001 (Early clinical data) |
| Pivotal Trial | Phase III Global Trial (NCT07099898) – Started Aug 2025 |
| Partnership | Exclusive worldwide rights (ex-China) from Hansoh Pharma |
| Key Indications | SCLC, Prostate Cancer, Colorectal Cancer, Osteosarcoma |
A Critical Unmet Need in Japan
Lung cancer remains the second most common cancer in Japan, with SCLC accounting for approximately 10-15% of all cases. The prognosis for patients with the extensive-stage form of the disease (ES-SCLC) is notably poor:
- 70% of SCLC patients are diagnosed at the extensive stage.
- High Relapse Rates: Most patients relapse following initial treatment.
- Survival Gap: The current median overall survival with standard-of-care for relapsed patients is only 8 months.
Deep Insights: Therapeutic Potential and Strategy
The granting of ODD in Japan provides GSK with several strategic advantages, including potential tax incentives and a period of market exclusivity, which are critical for rare or difficult-to-treat diseases like SCLC.
1. Targeting B7-H3: Ris-Rez utilizes a fully human monoclonal antibody to target B7-H3, a protein frequently overexpressed in several solid tumors. By linking this to a potent topoisomerase inhibitor payload, the ADC is designed to deliver cell-killing agents directly to the tumor site while minimizing systemic impact.
2. Accelerated Development: GSK’s global Phase III trial (NCT07099898) for relapsed ES-SCLC was initiated in August 2025, just months before this latest Japanese designation. This suggests a highly aggressive development timeline aimed at addressing the 8-month survival barrier currently faced by patients.
3. Expanding Oncology Footprint: Beyond SCLC, GSK is actively investigating Ris-Rez in prostate and colorectal cancers, indicating that the B7-H3 mechanism may serve as a cornerstone for GSK’s broader ADC oncology portfolio.
Eli Lilly Olumiant Alopecia Areata Treatment Approved by FDA for Pediatric Patients 12 and Older
Lilly Olumiant Alopecia Areata has received FDA approval for pediatric patients 12 and older, expanding treatment access based on Phase 3 BRAVE-AA-PEDS trial results showing […]
Lilly Onswik FDA Approval: Eli Lilly’s Weekly Basal Insulin Clears FDA for Type 2 Diabetes
The FDA has approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. Backed by the QWINT Phase […]
J&J TECVAYLI DARZALEX FASPRO Survival Data Redefine Long-Term Outlook in Early Multiple Myeloma Relapse
New MajesTEC-3 modeling from Johnson & Johnson finds that TECVAYLI plus DARZALEX FASPRO, used as early as second line, could give roughly 87% of relapsed/refractory […]
About Risvutatug Rezetecan
Risvutatug rezetecan is a novel investigational ADC. Under a licensing agreement with Hansoh Pharma, GSK holds the rights to progress the clinical development and commercialization of the drug globally, excluding Mainland China, Hong Kong, Macau, and Taiwan.
